Literature DB >> 8306005

NIH clinical trials and publication bias.

K Dickersin1, Y I Min.   

Abstract

OBJECTIVE: To investigate the association between trial characteristics, findings, and publication. The major factor hypothesized to be associated with publication was "significant" results, which included both statistically significant results and results assessed by the investigators to be qualitatively significant, when statistical testing was not done. Other factors hypothesized to have a possible association with publication were funding institute, funding mechanism (grant versus contract versus intramural), multicenter status, use of comparison groups, large sample size, type of control (parallel versus nonparallel), use of randomization and masking, type of analysis (by treatment received versus by treatment assigned), and investigator sex and rank.
DESIGN: Follow-up, by 1988 interview with the principal investigator or surrogate, of all clinical trials funded by the National Institutes of Health (NIH) in 1979, to learn of trial results and publication status. POPULATION: Two hundred ninety-three NIH trials, funded in 1979. MAIN OUTCOME MEASURE: Publication of clinical trial results.
RESULTS: Of the 198 clinical trials completed by 1988, 93% had been published. Trials with "significant" results were more likely to be published than those showing "nonsignificant" results (adjusted odds ratio [OR] = 12.30; 95% confidence interval [CI], 2.54 to 60.00). No other factor was positively associated with publication. Most unpublished trials remained so because investigators thought the results were "not interesting" or they "did not have enough time" (42.8%). Metaanalysis using data from this and 3 similar studies provided a combined unadjusted OR of 2.88 (95% CI, 2.13 to 3.89) for the association between significant results and publication.
CONCLUSIONS: Even when the overall publication rate is high, such as for trials funded by the NIH, publication bias remains a significant problem. Given the importance of trials and their utility in evaluating medical treatments, especially within the context of metaanalysis, it is clear that we need more reliable systems for maintaining information about initiated studies. Trial registers represent such a system but must receive increased financial support to succeed.

Mesh:

Year:  1993        PMID: 8306005

Source DB:  PubMed          Journal:  Online J Curr Clin Trials        ISSN: 1059-2725


  58 in total

Review 1.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

2.  Registering CIHR-funded randomized controlled trials: a global public good.

Authors:  David Moher; Alan Bernstein
Journal:  CMAJ       Date:  2004-09-28       Impact factor: 8.262

3.  Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO.

Authors:  Kay Dickersin; Iain Chalmers
Journal:  J R Soc Med       Date:  2011-12       Impact factor: 5.344

4.  Oral presentation bias: a retrospective cohort study.

Authors:  Evelyne Decullier; François Chapuis
Journal:  J Epidemiol Community Health       Date:  2007-03       Impact factor: 3.710

5.  Fate of biomedical research protocols and publication bias in France: retrospective cohort study.

Authors:  Evelyne Decullier; Véronique Lhéritier; François Chapuis
Journal:  BMJ       Date:  2005-06-20

6.  A review of the literature pertaining to the efficacy, safety, educational requirements, uses and usage of mechanical adjusting devices: Part 1 of 2.

Authors:  Shane H Taylor; Nicole D Arnold; Lesley Biggs; Christopher J Colloca; Dale R Mierau; Bruce P Symons; John J Triano
Journal:  J Can Chiropr Assoc       Date:  2004-03

Review 7.  Publication bias in clinical trials due to statistical significance or direction of trial results.

Authors:  Sally Hopewell; Kirsty Loudon; Mike J Clarke; Andrew D Oxman; Kay Dickersin
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

8.  The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials.

Authors:  R Kunz; A D Oxman
Journal:  BMJ       Date:  1998-10-31

Review 9.  Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.

Authors:  K G Marshall
Journal:  CMAJ       Date:  1996-06-15       Impact factor: 8.262

Review 10.  Assembling comparison groups to assess the effects of health care.

Authors:  I Chalmers
Journal:  J R Soc Med       Date:  1997-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.